BMY RSI Chart
Last 7 days
-1.2%
Last 30 days
-14.5%
Last 90 days
-10.3%
Trailing 12 Months
-35.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 45.5B | 0 | 0 | 0 |
2023 | 45.8B | 45.2B | 44.9B | 45.0B |
2022 | 47.0B | 47.1B | 46.7B | 46.2B |
2021 | 42.8B | 44.4B | 45.5B | 46.4B |
2020 | 31.0B | 34.9B | 39.4B | 42.5B |
2019 | 23.3B | 23.9B | 24.2B | 26.1B |
2018 | 21.0B | 21.6B | 22.0B | 22.6B |
2017 | 20.0B | 20.2B | 20.6B | 20.8B |
2016 | 16.9B | 17.6B | 18.5B | 19.4B |
2015 | 16.1B | 16.4B | 16.5B | 16.6B |
2014 | 16.4B | 16.2B | 16.1B | 15.9B |
2013 | 16.2B | 15.8B | 16.1B | 16.4B |
2012 | 21.5B | 20.5B | 18.9B | 17.6B |
2011 | 19.7B | 20.4B | 20.9B | 21.2B |
2010 | 19.3B | 19.4B | 19.4B | 19.5B |
2009 | 17.1B | 16.6B | 16.1B | 18.8B |
2008 | 0 | 16.3B | 17.0B | 17.7B |
2007 | 0 | 0 | 0 | 15.6B |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index
Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.
Returns of $10,000 invested in:
Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022
Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 01, 2024 | shanahan karin | acquired | - | - | 3,306 | evp, glob. prod. dev. & supply |
Apr 01, 2024 | shanahan karin | sold (taxes) | -63,376 | 52.99 | -1,196 | evp, glob. prod. dev. & supply |
Mar 10, 2024 | hoch lynelle | acquired | - | - | 4,351 | president, cell therapy org. |
Mar 10, 2024 | elkins david v | acquired | - | - | 64,326 | evp, chief financial officer |
Mar 10, 2024 | hirawat samit | sold | - | - | -11,705 | evp,chief med.offr.,drug dev. |
Mar 10, 2024 | caforio giovanni | sold | - | - | -57,536 | executive chair of the board |
Mar 10, 2024 | hoch lynelle | sold (taxes) | -70,357 | 53.79 | -1,308 | president, cell therapy org. |
Mar 10, 2024 | plenge robert m | sold (taxes) | -105,697 | 53.79 | -1,965 | evp, chief research officer |
Mar 10, 2024 | gallman cari | sold (taxes) | -37,437 | 53.79 | -696 | evp, corporate affairs |
Mar 10, 2024 | leung sandra | sold (taxes) | -896,141 | 53.79 | -16,660 | evp, general counsel |
Which funds bought or sold BMY recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 07, 2024 | KEATING INVESTMENT COUNSELORS INC | reduced | -42.05 | -398,379 | 629,719 | 0.20% |
May 07, 2024 | HYMAN CHARLES D | reduced | -1.05 | 476,000 | 10,862,000 | 0.60% |
May 07, 2024 | PANAGORA ASSET MANAGEMENT INC | reduced | -37.22 | -29,678,800 | 58,517,800 | 0.30% |
May 07, 2024 | OPPENHEIMER & CO INC | added | 13.79 | 1,999,730 | 11,868,200 | 0.20% |
May 07, 2024 | Capital Wealth Planning, LLC | reduced | -3.35 | 16,510 | 783,081 | 0.01% |
May 07, 2024 | NEW SOUTH CAPITAL MANAGEMENT INC | unchanged | - | 20,991 | 389,859 | 0.02% |
May 07, 2024 | NTV Asset Management LLC | added | 9.36 | 246,399 | 1,827,880 | 0.28% |
May 07, 2024 | Illinois Municipal Retirement Fund | reduced | -1.6 | 1,262,000 | 32,817,000 | 0.50% |
May 07, 2024 | Mengis Capital Management, Inc. | unchanged | - | - | 6,488,540 | 1.22% |
May 07, 2024 | AllSquare Wealth Management LLC | reduced | -28.89 | -90,451 | 273,645 | 0.16% |
Unveiling Bristol-Myers Squibb Co's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Bristol-Myers Squibb Co)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 358.5B | 85.6B | 9.32 | 4.19 | ||||
MRK | 328.0B | 61.4B | 142.26 | 5.34 | ||||
AMGN | 164.9B | 29.5B | 43.82 | 5.58 | ||||
PFE | 160.3B | 57.8B | 127.84 | 2.77 | ||||
GILD | 80.9B | 27.4B | 166.89 | 2.95 | ||||
TEVA | 17.8B | 16.0B | -36.03 | 1.11 | ||||
MID-CAP | ||||||||
PRGO | 4.2B | 4.6B | -550.77 | 0.93 | ||||
ALKS | 4.1B | 1.7B | 9.39 | 2.36 | ||||
BHC | 2.6B | 9.0B | -5.66 | 0.29 | ||||
AMPH | 2.0B | 644.4M | 14.77 | 3.15 | ||||
SMALL-CAP | ||||||||
TLRY | 1.5B | 743.2M | -4.27 | 2.02 | ||||
TXMD | 23.3M | 1.3M | -2.27 | 17.89 | ||||
ACRX | 17.5M | - | -0.95 | 0.22 | ||||
AGRX | 2.7M | 19.6M | -0.19 | 0.14 | ||||
ACOR | 1.1M | 117.6M | 0 | 0.01 |
Bristol-Myers Squibb Co News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | 3.4% | 11,865 | 11,477 | 10,966 | 11,226 | 11,337 | 11,406 | 11,218 | 11,887 | 11,648 | 11,985 | 11,624 | 11,703 | 11,073 | 11,068 | 10,540 | 10,129 | 10,781 | 7,945 | 6,007 | 6,273 | 5,920 |
Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8,158 | 8,038 | 7,430 | 7,119 | 5,453 | 4,217 | 4,301 | 4,096 |
Costs and Expenses | 138.5% | 23,381 | 9,803 | 8,829 | 9,367 | 8,567 | 9,547 | 9,009 | 9,929 | 9,961 | 10,127 | 9,467 | 10,150 | 8,543 | 21,519 | 8,283 | 8,502 | 11,085 | 8,074 | 4,658 | 4,497 | 3,941 |
S&GA Expenses | 14.2% | 2,367 | 2,073 | 2,003 | 1,934 | 1,762 | 2,266 | 1,930 | 1,787 | 1,831 | 2,354 | 1,788 | 1,882 | 1,666 | 2,721 | 1,706 | 1,628 | 1,606 | 1,734 | 1,055 | 1,076 | 1,006 |
R&D Expenses | 8.8% | 2,695 | 2,478 | 2,242 | 2,258 | 2,321 | 2,510 | 2,418 | 2,321 | 2,260 | 2,518 | 2,980 | 2,478 | 2,219 | 2,655 | 2,499 | 2,522 | 2,372 | 2,097 | 1,378 | 1,325 | 1,348 |
EBITDA Margin | -78.2% | 0.09* | 0.40* | 0.41* | 0.41* | 0.41* | 0.39* | 0.39* | 0.38* | 0.38* | 0.40* | 0.14* | 0.15* | 0.15* | 0.08* | 0.31* | 0.26* | 0.22* | - | - | - | - |
Income Taxes | 545.5% | 392 | -88.00 | 203 | -218 | 503 | -166 | 601 | 529 | 404 | -514 | 605 | 492 | 501 | -424 | 379 | 1,707 | 462 | 931 | -17.00 | 337 | 264 |
Earnings Before Taxes | -787.9% | -11,516 | 1,674 | 2,137 | 1,859 | 2,770 | 1,859 | 2,209 | 1,958 | 1,687 | 1,858 | 2,157 | 1,553 | 2,530 | -10,451 | 2,257 | 1,627 | -304 | -129 | 1,349 | 1,776 | 1,979 |
EBT Margin | -168.5% | -0.13* | 0.19* | 0.19* | 0.19* | 0.19* | 0.17* | 0.17* | 0.16* | 0.15* | 0.17* | -0.09* | -0.09* | -0.09* | -0.16* | 0.09* | 0.07* | 0.09* | - | - | - | - |
Net Income | -525.9% | -11,911 | 2,797 | 1,928 | 4.00 | 2,262 | 3,365 | 1,606 | 8.00 | 5.00 | 3,917 | 1,546 | -6.00 | -8.00 | -10,027 | 1,872 | -85.00 | -775 | -1,056 | 1,353 | 1,432 | 1,710 |
Net Income Margin | -202.1% | -0.13* | 0.13* | 0.10* | 0.09* | 0.12* | 0.12* | 0.15* | 0.15* | 0.12* | 0.12* | -0.19* | -0.18* | -0.19* | -0.21* | 0.00* | -0.02* | 0.03* | - | - | - | - |
Free Cashflow | -35.0% | 2,550 | 3,922 | 4,409 | 1,628 | 2,692 | 2,960 | 3,440 | 1,989 | 3,559 | 3,737 | 4,996 | 2,850 | 3,651 | 3,072 | 2,114 | 4,362 | 3,751 | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 4.1% | 99,031 | 95,159 | 91,263 | 93,489 | 94,281 | 96,820 | 98,196 | 100,357 | 103,034 | 109,314 | 110,893 | 110,797 | 112,435 | 118,481 | 125,536 | 128,076 | 129,285 | 129,944 | 57,433 | 55,163 | 34,834 |
Current Assets | -9.8% | 28,669 | 31,770 | 27,632 | 28,074 | 27,086 | 27,273 | 26,796 | 30,186 | 30,121 | 33,262 | 31,443 | 29,161 | 27,111 | 30,192 | 34,277 | 34,343 | 31,853 | 29,354 | 40,191 | 37,716 | 17,093 |
Cash Equivalents | -18.6% | 9,330 | 11,464 | 7,514 | 8,372 | 9,048 | 9,325 | 7,957 | 10,960 | 12,579 | 14,316 | 13,879 | 11,397 | 11,321 | 14,973 | 19,860 | 20,362 | 16,246 | 12,820 | 30,489 | 28,404 | 7,335 |
Inventory | 12.1% | 2,985 | 2,662 | 2,436 | 2,364 | 2,605 | 2,339 | 2,074 | 2,142 | 2,104 | 2,095 | 2,163 | 2,137 | 1,953 | 2,074 | 1,949 | 2,384 | 2,836 | 4,293 | 1,192 | 1,308 | 1,283 |
Net PPE | 1.6% | 6,750 | 6,646 | 6,481 | 6,355 | 6,279 | 6,255 | 6,035 | 5,970 | 6,047 | 6,049 | 5,868 | 5,795 | 5,763 | 5,886 | 5,740 | 5,777 | 6,112 | 6,252 | 4,830 | 4,849 | 4,985 |
Goodwill | 2.7% | 21,738 | 21,169 | 21,147 | 21,163 | 21,162 | 21,149 | 21,112 | 20,446 | 20,500 | 20,502 | 20,519 | 20,529 | 20,524 | 20,547 | 20,517 | 20,578 | 22,452 | 22,488 | 6,513 | 6,533 | - |
Liabilities | 25.6% | 82,483 | 65,674 | 62,201 | 61,459 | 62,395 | 65,702 | 65,462 | 67,696 | 71,389 | 73,308 | 73,609 | 73,923 | 74,762 | 80,599 | 75,306 | 78,916 | 79,308 | 78,246 | 39,679 | 39,012 | 19,517 |
Current Liabilities | 16.0% | 25,822 | 22,262 | 23,462 | 20,150 | 19,085 | 21,890 | 18,930 | 20,915 | 22,821 | 21,868 | 21,460 | 18,991 | 17,330 | 19,080 | 20,464 | 23,421 | 19,232 | 18,304 | 10,489 | 9,711 | 8,841 |
Short Term Borrowings | 98.5% | 6,190 | 3,119 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt | 35.0% | 49,487 | 36,653 | 32,137 | 34,656 | 35,078 | 35,056 | 36,966 | 37,107 | 37,450 | 39,605 | 39,677 | 42,503 | 44,505 | 48,336 | 44,614 | 46,106 | 46,105 | 46,150 | 24,390 | 24,433 | 5,635 |
LT Debt, Non Current | 35.0% | 49,487 | 36,653 | 32,137 | 34,656 | 35,078 | 35,056 | 36,966 | 37,107 | 37,450 | 39,605 | 39,677 | 42,503 | 44,505 | 48,336 | 41,364 | 41,853 | 42,844 | 43,387 | 24,390 | 24,433 | 5,635 |
Shareholder's Equity | -44.0% | 16,490 | 29,430 | 28,998 | 57.00 | 45,140 | 25,503 | 44,956 | 292 | 43,756 | 60.00 | 22,625 | 66.00 | 43,852 | 60.00 | 50,230 | 49,160 | 49,977 | 43,709 | 17,754 | 16,151 | 15,317 |
Retained Earnings | -45.6% | 15,640 | 28,766 | 28,218 | 27,449 | 26,568 | 25,503 | 24,675 | 24,217 | 23,948 | 23,820 | 22,625 | 22,168 | 22,204 | 21,281 | 32,414 | 31,565 | 32,671 | 34,474 | 36,555 | 35,870 | 35,109 |
Additional Paid-In Capital | -0.1% | 45,655 | 45,684 | 44,849 | 45,299 | 45,140 | 45,165 | 44,956 | 44,375 | 43,756 | 44,361 | 44,292 | 44,064 | 43,852 | 44,325 | 44,435 | 44,444 | 43,254 | 43,709 | 2,206 | 2,150 | 2,103 |
Shares Outstanding | - | - | - | - | - | - | - | 2,126 | 2,135 | 2,129 | - | 2,220 | 2,222 | 2,233 | - | 2,260 | 2,254 | 2,263 | - | 1,629 | 1,636 | 1,636 |
Minority Interest | 5.5% | 58.00 | 55.00 | 64.00 | 57.00 | 62.00 | 57.00 | 63.00 | 61.00 | 65.00 | 60.00 | 71.00 | 66.00 | 68.00 | 60.00 | 72.00 | 66.00 | 66.00 | 100 | 106 | 102 | 99.00 |
Float | - | - | - | - | 133,499 | - | - | - | 164,301 | - | - | - | 148,383 | - | - | - | 132,443 | - | - | - | 74,102 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -33.3% | 2,834 | 4,252 | 4,751 | 1,887 | 2,970 | 3,306 | 3,687 | 2,261 | 3,812 | 4,057 | 5,266 | 3,060 | 3,824 | 3,355 | 2,267 | 4,493 | 3,937 | 2,181 | 2,556 | 2,083 | 1,390 |
Share Based Compensation | 4.7% | 133 | 127 | 132 | 137 | 122 | 119 | 115 | 116 | 107 | 133 | 142 | 157 | 151 | 171 | 185 | 213 | 210 | 284 | 56.00 | 48.00 | 53.00 |
Cashflow From Investing | -1357.5% | -19,618 | -1,346 | -410 | -329 | -210 | 1,213 | -2,081 | -289 | 95.00 | 401 | -976 | 180 | -143 | -11,812 | -213 | 556 | 610 | -12,179 | 491 | 715 | 1,060 |
Cashflow From Financing | 1414.4% | 14,644 | 967 | -5,160 | -2,173 | -3,050 | -3,246 | -4,543 | -3,520 | -5,653 | -3,967 | -1,780 | -3,182 | -7,295 | 3,483 | -2,587 | -993 | -1,054 | -7,677 | -941 | 18,268 | -2,029 |
Dividend Payments | 4.5% | 1,212 | 1,160 | 1,191 | 1,197 | 1,196 | 1,145 | 1,154 | 1,150 | 1,185 | 1,099 | 1,090 | 1,099 | 1,108 | 1,021 | 1,016 | 1,021 | 1,017 | 668 | 671 | 671 | 669 |
Buy Backs | - | - | - | 4,000 | 905 | 250 | 2,416 | 701 | - | 5,000 | 2,751 | 525 | 1,236 | 1,775 | 1,465 | - | - | 81.00 | 7,000 | 300 | - | - |
CONSOLIDATED STATEMENTS OF EARNINGS - USD ($) $ in Millions | 3 Months Ended | |||
---|---|---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |||
Total Revenues | $ 11,865 | $ 11,337 | ||
Cost of products sold | [1] | 2,932 | 2,566 | |
Marketing, selling and administrative | 2,367 | 1,762 | ||
Research and development | 2,695 | 2,321 | ||
Acquired IPRD | 12,949 | 75 | ||
Amortization of acquired intangible assets | 2,357 | 2,256 | ||
Other (income)/expense, net | 81 | (413) | ||
Total Expenses | 23,381 | 8,567 | ||
(Loss)/Earnings before income taxes | (11,516) | 2,770 | ||
Income tax provision | 392 | 503 | ||
Net (loss)/earnings | (11,908) | 2,267 | ||
Noncontrolling interest | 3 | 5 | ||
Net (loss)/earnings attributable to BMS | $ (11,911) | $ 2,262 | ||
(Loss)/Earnings per common share: | ||||
Basic (usd per share) | $ (5.89) | $ 1.08 | ||
Diluted (usd per share) | $ (5.89) | $ 1.07 | ||
Net product sales | ||||
Total Revenues | $ 11,559 | $ 11,048 | ||
Alliance and other revenues | ||||
Total Revenues | $ 306 | $ 289 | ||
|
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 9,330 | $ 11,464 |
Marketable debt securities | 340 | 816 |
Receivables | 10,447 | 10,921 |
Inventories | 2,985 | 2,662 |
Other current assets | 5,567 | 5,907 |
Total Current assets | 28,669 | 31,770 |
Property, plant and equipment | 6,750 | 6,646 |
Goodwill | 21,738 | 21,169 |
Other intangible assets | 32,760 | 27,072 |
Deferred income taxes | 2,723 | 2,768 |
Marketable debt securities | 367 | 364 |
Other non-current assets | 6,024 | 5,370 |
Total Assets | 99,031 | 95,159 |
Current liabilities: | ||
Short-term debt obligations | 6,190 | 3,119 |
Accounts payable | 3,539 | 3,259 |
Other current liabilities | 16,093 | 15,884 |
Total Current liabilities | 25,822 | 22,262 |
Deferred income taxes | 442 | 338 |
Long-term debt | 49,487 | 36,653 |
Other non-current liabilities | 6,732 | 6,421 |
Total Liabilities | 82,483 | 65,674 |
Commitments and Contingencies | ||
BMS Shareholders’ equity: | ||
Preferred stock | 0 | 0 |
Common stock | 292 | 292 |
Capital in excess of par value of stock | 45,655 | 45,684 |
Accumulated other comprehensive loss | (1,400) | (1,546) |
Retained earnings | 15,640 | 28,766 |
Less cost of treasury stock | (43,697) | (43,766) |
Total BMS Shareholders’ equity | 16,490 | 29,430 |
Noncontrolling interest | 58 | 55 |
Total Equity | 16,548 | 29,485 |
Total Liabilities and Equity | $ 99,031 | $ 95,159 |
 | Dr. Giovanni Caforio M.D. |
---|---|
 | bms.com |
 | Pharmaceuticals |
 | 34300 |